A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Mansoor R Mirza1 Rigshospitalet, Copenhagen University Hospital & Nordic Society of Gynaecologic Oncology Clinical Trial Unit, Copenhagen, Denmark

Antonio González-Martín2 Medical Oncology Department & Program in Solid Tumours–CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, & Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain

Whitney S Graybill3 Medical University of South Carolina, Charleston, SC, USA

David M O’Malley4 The Ohio State University & the James Comprehensive Cancer Center, Columbus, OH, USA

Lydia Gaba5 Hospital Clinic de Barcelona, Translational Genomics & Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain

Oi Wah Stephanie Yap6 University Gynecologic Oncology, Atlanta, GA, USA

Eva M Guerra7 Breast & Gynaecological Cancer Unit, Hospital Ramón y Cajal, Madrid, Spain

Peter G Rose8 Cleveland Clinic, Cleveland, OH, USA

Jean-François Baurain9 Université Catholique de Louvain & Cliniques Universitaires Saint-Luc, Brussels, Belgium

Sharad A Ghamande10 Georgia Cancer Center, Augusta University, Augusta, GA, USA

Hannelore Denys11 Ghent University Hospital, Ghent, Belgium

Emily Prendergast12 Minnesota Oncology, Minneapolis, Minnesota, USA, when the analysis was conducted; currently at Intermountain Medical Group, Salt Lake City, UT, USA

Carmela Pisano13 Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

Philippe Follana14 Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) & Département D’Oncologie Médicale, Centre Antoine Lacassagne, Nice, France

Klaus Baumann15 Arbeitsgemeinschaft Gynäkologische Onkologie & the Department of Gynecology & Obstetrics, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany

Paula M Calvert16 Cancer Trials Ireland, Dublin, Ireland, when the analysis was conducted; currently at University Hospital Waterford, Waterford, Ireland

Jacob Korach17 Gynecologic Oncology Department, The Chaim Sheba Medical Center, Sackler Medical School, Tel Aviv University, Ramat Gan, Israel

Yong Li18 GSK, Waltham, MA, USA, when the analysis was conducted; currently at Adagio Therapeutics, Waltham, MA, USA

Izabela A Malinowska19 GSK, Waltham, MA, USA

Divya Gupta18 GSK, Waltham, MA, USA, when the analysis was conducted; currently at Adagio Therapeutics, Waltham, MA, USA

Bradley J Monk20 HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA, when the study was conducted; present affiliation GOG Foundation; Florida Cancer Specialists & Research Institute, West Palm Beach, FL, USA

show all

A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date